Chemotherapy-Induced Neutropenia
Conditions
Interventions
Sponsors
Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients receiving a high-FN risk chemotherapy regimen (appendix 1); patients receiving a moderate FN-risk chemotherapy regimen who meet any of the factors that contribute to the increased risk factor (appendix 2 and 3); or patients with previous FN during the previous chemotherapy cycle Patients with dose-limiting neutropenia events; 2. Researchers believe that they can benefit; 3. Participants were willing to join in this study, and written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have allergic for mecapegfilgrastim; 2. Patients who have mental illness or nervous system cannot cooperate; 3. Patients with pregnant or lactating women;Women of childbearing potential are unwilling or unable to take effective contraceptive measures; 4. The researchers think inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The incidence of Febrile Neutropenia (FN) in cycle 1;2. The incidence of Febrile Neutropenia (FN) in other cycle (exclude the first cycle); | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The incidence of grade 3, 4 neutropenia in cycle 1;2. The incidence of grade 3, 4 neutropenia in other cycle (exclude the first cycle);3. The incidence of chemotherapy administration dose adjustment due to neutropenia;4. The incidence of chemotherapy delay due to neutropenia;5. The rate of hospitalization due to neutropenia;6. The rate of antibiotic administration due to neutropenia;7. The incidence of short-acting whitening remedy therapy;8. The time to neutropenia recovery during the period of therapy;9. Safety: The incidence and severity of all adverse events (AEs); | — |
Contacts
Public ContactLiu Yunjiang
Fourth Hospital of Hebei Medical University
Outcome results
None listed